• SPX
  • $5,756.98
  • 0.78 %
  • $44.29
  • DJI
  • $42,102.23
  • 0.74 %
  • $307.62
  • N225
  • $38,474.90
  • 1.11 %
  • $421.23
  • FTSE
  • $8,179.52
  • -0.06 %
  • -$4.72
  • IXIC
  • $18,351.70
  • 0.94 %
  • $171.71
Altamira Therapeutics Ltd. (CYTO) Stock Price, News & Analysis

Altamira Therapeutics Ltd. (CYTO) Stock Price, News & Analysis

Currency in USD Disclaimer

$0.51

$0.02

(5.05%)

Day's range
$0.48
Day's range
$0.51
50-day range
$0.45
Day's range
$0.9384
  • Country: BM
  • ISIN: BMG0360L1349
52 wk range
$0.45
Day's range
$17.2


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score -3.45
  • Piotroski Score 4.00
  • Grade N/A
  • Symbol (CYTO)
  • Company Altamira Therapeutics Ltd.
  • Price $0.51
  • Changes Percentage (5.05%)
  • Change $0.02
  • Day Low $0.48
  • Day High $0.51
  • Year High $17.20

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also involved in the development of RNA therapeutics for extrahepatic therapeutic targets, including OligoPhore and SemaPhore platforms that are in preclinical stage for oligonucleotide and mRNA delivery; AM-125 that is in phase II clinical trial for the intranasal treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. It operates in Switzerland, the United States, Europe, and Australia. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. Altamira Therapeutics Ltd. was founded in 2003 and is headquartered in Hamilton, Bermuda.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 04/09/2025
  • Fiscal Year End N/A

  • Average Stock Price Target $0.00
  • High Stock Price Target $0.00
  • Low Stock Price Target $0.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$16.63
  • Trailing P/E Ratio -0.09
  • Forward P/E Ratio -0.09
  • P/E Growth -0.09
  • Net Income $-7,270,038

Income Statement

Quarterly

Annual

Latest News of CYTO

The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to Stocks.News!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.